EXEL
What one share of Exelixis holds
Biological Products, (No Diagnostic Substances)
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S.
Exelixis’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-03; the balance sheet is as of 2026-07-03.
| Sales | $9.01 |
|---|---|
| Profit | $3.18 |
| Capex (buildings and equipment) | $0.04 |
| Free cash flow | $4.33 |
| Cash and investments | $5.56 |
| Book value | $7.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.76 | −$0.28 | $0.01 | $0.83 | — | $0.31 |
| 2017 | $1.45 | $0.49 | $0.07 | $0.46 | — | $0.96 |
| 2018 | $2.73 | $2.21 | $0.11 | $1.22 | — | $4.29 |
| 2019 | $3.07 | $1.02 | $0.04 | $1.63 | — | $5.53 |
| 2020 | $3.11 | $0.35 | $0.10 | $0.56 | — | $6.03 |
| 2021 | $4.45 | $0.72 | $0.17 | $1.08 | — | $6.93 |
| 2022 | $4.96 | $0.56 | $0.09 | $1.03 | — | $7.68 |
| 2023 | $5.69 | $0.65 | $0.13 | $0.91 | — | $7.48 |
| 2024 | $7.32 | $1.76 | $0.10 | $2.27 | — | $7.97 |
| 2025 | $8.23 | $2.78 | $0.03 | $3.11 | — | $8.23 |